Lv32
270 积分 2024-05-22 加入
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study
1天前
待确认
Single–amino acid variants in target epitopes can confer resistance to antibody-based therapies
1天前
已完结
Cis- and trans-binding chimeric costimulatory receptors enhance T-cell fitness and tumor control
1天前
已完结
Immunological conversion of triple-negative breast cancer by engineered extracellular vesicle-mediated pyroptosis
1天前
已完结
The therapeutic antibody sacituzumab induces trophoblast cell-surface antigen-2 conformational rearrangement
1天前
已完结
Sacituzumab Tirumotecan in Participants With Advanced or Metastatic Urothelial Carcinoma and Disease Progression after Chemotherapy and Immune Checkpoint Inhibitors
1天前
已完结
Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development
1天前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
1天前
求助中
A TNBC-targeting nano-radiosensitizer reverses radioresistance by synergizing GSH scavenging with dual inhibition of Trop2 and lncRNA MNX1-AS1
1天前
已完结
Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate
1天前
已完结
皖公网安备34019202002308
